Vibe Bio

Of the Eight IL-4Rα Assets in Phase III Right Now, Seven Are Chinese. The Eighth Is Licensed to China Too. IL-4Rα is the mechanism behind Dupixent, one of the best-selling drugs in the world, used to treat atopic dermatitis (eczema), asthma, and other typ

Daiichi Sankyo's anti-TLR7 antibody just completed Phase 1b/2 - here's how VibeOne sees the TLR7/8 landscape in lupus today. The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at on

Eli Lilly and Company bought Morphic for $3.2B in July 2024 - here's the Integrin α4β7 landscape today.We worked with our friends at Sleuth to assess the risks of MORF-057 and examine the assets in the space.First, the landscape: 51 assets across 54 compa

A Framework for Evaluating Opportunities Before Formal Diligence Data is exploding, timelines are shrinking, and competition is fierce. Long-term growth in pharma increasingly depends on a company's ability to source, evaluate, and secure the right extern

The best kidney drugs weren't built for kidneys.Our AI, VibeOne, recently generated a landscaped & analyzed 100 drug programs in Chronic Kidney Disease (CKD). CKD is a burgeoning area of interest for pharma - it's a condition affecting 850 million people

As JPM26 fast approaches, the obesity market is shifting… from how much weight patients lose, to what kind of weight they lose.…and China has a strong presence. Check out Laekna (2105.HK).Fresh off their massive collaboration with Eli Lilly and Company fo

Drug hunters need to watch Urea Cycle Disorders! When Amgen bought Horizon for $27B+, I became fascinated with this space. Patients still don't have great treatments: gene therapies (cost) and ERTs (patient experience) leave much to be desired.After learn

Is the kidney disease the next big therapeutic area? Numerous biopharmas have approached Vibe Bio to use our AI, VibeOne, to help identify new kidney indications for them to pursue. Why? Our insight: the momentum in this therapeutic area emerges as the FD

The pace of BD&L has never been faster - or more complex Data is exploding, timelines are shrinking, and competition is fierce. Traditional diligence models can't keep pace with today's deal flow. Scientific, clinical, and regulatory data are multiplying

Fabry disease may seem niche, but it's becoming a bellwether for how global innovation and modality shifts are reshaping rare disease pipelines. Few teams are tracking just how quickly the Fabry landscape is evolving. Using VibeOne, we mapped the global F